Objective: To assess the results of transurethral implantation of Macroplastique® in women with stress incontinence secondary to urethral sphincter deficiency using subjective and objective outcome measures. Methods: A total of 60 women with genuine stress incontinence secondary to intrinsic urethral sphincter deficiency were treated with transurethral implantation of Macroplastique. The patients had undergone a mean of 1.9 (range 0–7) previous episodes of continence surgery. Up to three treatment episodes were used, if necessary. The outcome was assessed by telephone interview (56 patients, mean follow–up period 19 months) and videocystometry (41 patients, mean follow–up period 16 months). Transurethral ultrasound scanning was performed in a further 9 patients. Results: Symptomatically, 19.6% of the women interviewed by telephone considered themselves cured of their incontinence or were no longer using pads. A further 41.1% said their symptoms had significantly improved. Pad usage was reduced from a median of five to three pads per day (p<0.001). Videocystometry in 41 women (mean follow–up period 16 months) was normal in 16 patients (39%) and showed genuine stress incontinence in 18 (43.9%) and detrusor instability in 12 patients (29.3%). Overall, 71.4% stated that they would undergo the procedure again under the same circumstances, and 80.4% would recommend this form of treatment to a friend with the same condition. Transurethral ultrasound scanning was performed in 9 patients (5 subjectively improved or cured, 1 patient with persistent symptoms but normal cystometry, and 3 patients with persistent genuine stress incontinence). Hyperechoic foci were seen surrounding the proximal urethra, consistent with implanted Macroplastique boluses. When completely encircling the urethra, the outcome was generally good. A total of 10 patients have undergone or are awaiting open surgery, and 3 are awaiting repeat implantation. Conclusion: Sustained improvement or cure of genuine stress incontinence has been achieved using Macroplastique in a large proportion of women with intrinsic sphincter deficiency, often following previous unsuccessful continence surgery. Transurethral ultrasound may prove to be a clinically useful imaging technique for the assessment and subsequent management of treatment failure following Macroplastique implantation.

1.
Blaivas JG, Olsen CA: Stress incontinence: Classification and surgical approach. J Urol 1988;139:727–731.
2.
Bergman A, Elia G: Three surgical procedures for genuine stress incontinence: Five–year follow–up of a prospective randomized study. Am J Obstet Gynecol 1995;173:66–71.
3.
Summit RL, Bent AE, Ostergard DA, Harriss TA: Suburethral sling procedure for genuine stress incontinence and low urethral closure pressure: A continued experience. Int Urogynecol J 1992;3:18–21.
4.
McGuire EJ, Lytton B: Pubovaginal sling procedure for stress incontinence. J Urol 1987; 119:81–84.
5.
Kieswetter H, Fischer M, Wober L, Flamm J: Endoscopic implantation of collagen (GAX) for the treatment of urinary incontinence. Br J Urol 1992;69:22–25.
6.
Monga AK, Robinson D, Stanton SL: Periurethral collagen injections for genuine stress incontinence: A 2–year follow–up. Br J Urol 1995;76:156–160.
7.
Harriss DR, Iacovou RJ, Lemberger RJ: Peri–urethral silicone microimplants (Macroplastique®) for the treatment of genuine stress incontinence. Br J Urol 1996;78:722–728.
8.
Sheriff MK, Foley S, McFarlane J, Nauth–Misir R, Shah PJ: Endoscopic correction of intractable stress incontinence with silicone micro–implants. Eur Urol 1997;32:284–288.
9.
Richardson TD, Kennelly MJ, Faeber GJ: Endoscopic injection of glutaraldehyde cross–linked collagen for the treatment of intrinsic sphincter deficiency in women. Urology 1995; 46:378–381.
10.
Leonhardt C, Krysl J, Arenson AM, Herschorn S: Periurethral injection of collagen in the treatment of urinary stress incontinence: Ultrasonographic appearance. Can Assoc Radiol J 1995;46:189–193.
11.
Carr LK, Herschorn S, Leonhardt C: Magnetic resonance imaging after intraurethral collagen injected for stress urinary incontinence. J Urol 1996;155:1253–1255.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.